Oral COVID-19 vaccine beckons, as ImmunityBio licenses iosBio techImmunityBio has licensed technology underpinning a COVID-19 vaccine that could be administered orally rather than by injection from Share XOral COVID-19 vaccine beckons, as ImmunityBio licenses iosBio techhttps://pharmaphorum.com/news/oral-covid-19-vaccine-beckons-as-immunitybio-licenses-iosbio-tech/
RNAi biotech Atalanta debuts with $110m plus Biogen and Roche CNS tie-upsUS biotech Atalanta Therapeutics has come out of stealth mode backed with $110m from Biogen and Roche, who Share XRNAi biotech Atalanta debuts with $110m plus Biogen and Roche CNS tie-upshttps://pharmaphorum.com/news/rnai-biotech-atalanta-debuts-with-110m-plus-biogen-and-roche-cns-tie-ups/
Chi-Med agrees R&D partnership with InmageneChina’s Chi-Med and Inmagene Biopharmaceuticals have agreed a strategic partnership to develop preclinical drug candidates for potential treatment Share XChi-Med agrees R&D partnership with Inmagenehttps://pharmaphorum.com/news/chi-med-agrees-rd-partnership-with-inmagene/
Coordinating and delivering research in the pandemic: The UK approachThe acute phase of the COVID-19 pandemic tested the UK’s capacity and capability to rapidly deliver crucial clinical Share XCoordinating and delivering research in the pandemic: The UK approachhttps://pharmaphorum.com/webinars/uk-covid-coroavirus-research-nihr/
Resourceful or risky? The UK’s controversial COVID-19 vaccine strategyAs COVID-19 vaccines are hastily deployed in the UK for priority groups, a debate rages over the government’s Share XResourceful or risky? The UK’s controversial COVID-19 vaccine strategyhttps://pharmaphorum.com/r-d/views-analysis-r-d/resourceful-or-risky-the-uks-controversial-covid-19-vaccine-strategy/
The Alderley Park Discovery Podcast: Life science skills, staffing and supportEpisode two of the Alderley Park Discovery Podcast covers access to skills in the life sciences sector, with Share XThe Alderley Park Discovery Podcast: Life science skills, staffing and supporthttps://pharmaphorum.com/podcast/alderley-park-life-science-skills-staffing/
Coordinating and delivering research in the pandemic: The UK approachThe acute phase of the COVID-19 pandemic tested the UK’s capacity and capability to rapidly deliver crucial clinical Share XCoordinating and delivering research in the pandemic: The UK approachhttps://pharmaphorum.com/webinars/uk-covid-coroavirus-research-nihr/
Increasing patient engagement with UK clinical trialsPharmaceutical companies often struggle to actively involve patients in the design phase of clinical trials but doing so Share XIncreasing patient engagement with UK clinical trialshttps://pharmaphorum.com/webinars/uk-regulatory-pathway-patient-engagement-trials/
Introducing the new NIHR National Patient Recruitment CentresThe five new NIHR National Patient Recruitment Centres (NPRCs) are set to shape the future of commercial clinical Share XIntroducing the new NIHR National Patient Recruitment Centreshttps://pharmaphorum.com/webinars/nihr-national-patient-recruitment-centres/
J+D FORECASTING MAKES THE PHARMA FORECASTING EXPERIENCE EVEN BETTERFC+, Pharma Forecasting Software has been upgraded Share XJ+D FORECASTING MAKES THE PHARMA FORECASTING EXPERIENCE EVEN BETTERhttps://pharmaphorum.com/partner-content/jd-forecasting-makes-the-pharma-forecasting-experience-even-better/
PPE for Infection Control Market Will Touch $17.1 Billion By 2026Global Market Insights, Inc., report forecasts the personal protective equipment for infection control industry to grow at a Share XPPE for Infection Control Market Will Touch $17.1 Billion By 2026https://pharmaphorum.com/partner-content/ppe-for-infection-control-market-will-touch-17-1-billion-by-2026/
Dermatology Devices Market Size Will Achieve 11.9% CAGR From 2019 To 2025The global dermatology devices market size is expected to reach USD 20 billion by 2025, at a CAGR of Share XDermatology Devices Market Size Will Achieve 11.9% CAGR From 2019 To 2025https://pharmaphorum.com/partner-content/dermatology-devices-market-size-will-achieve-11-9-cagr-from-2019-to-2025/
